Latest Licensing Deals News

Page 5 of 9
Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.
Victor Sage
Victor Sage
26 Aug 2025
Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.
Maxwell Dee
Maxwell Dee
26 Aug 2025
Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.
Ada Torres
Ada Torres
26 Aug 2025
Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.
Victor Sage
Victor Sage
26 Aug 2025
Metallium Ltd has partnered with Rice University to advance its Flash Joule Heating technology, targeting a breakthrough in rare earth element separation that could reduce Western dependence on Chinese refining. This collaboration seeks to simplify or bypass the costly solvent extraction process dominating the industry.
Maxwell Dee
Maxwell Dee
25 Aug 2025
Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.
Ada Torres
Ada Torres
20 Aug 2025
AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.
Ada Torres
Ada Torres
19 Aug 2025
Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.
Ada Torres
Ada Torres
12 Aug 2025
Syntara Limited has received FDA guidance recommending a Phase 2 controlled trial for its lead drug amsulostat in myelofibrosis, setting the stage for a pivotal Phase 3 study. The company is poised to refine its clinical strategy while advancing a diverse pipeline with key data milestones ahead.
Ada Torres
Ada Torres
11 Aug 2025
Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.
Ada Torres
Ada Torres
31 July 2025
Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.
Sophie Babbage
Sophie Babbage
31 July 2025
FirstWave Cloud Technology reports a slight revenue decline in Q4 FY25, offsets challenges with strategic restructuring and a new AWS marketplace partnership.
Sophie Babbage
Sophie Babbage
31 July 2025